Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Conference Call November 13, 2023 8:00 AM ET

Company Participants

Stephanie Lee - Vice President, Special Projects

Matt Gline - Chief Executive Officer

Mayukh Sukhatme - President and Chief Investment Officer

Frank Torti - Managing Director, Vant Chair

Conference Call Participants

David Risinger - Leerink Partners

Brian Cheng - JPMorgan

Yaron Werber - TD Cowen

Corinne Jenkins - Goldman Sachs

Robyn Karnauskas - Truist Securities

Louise Chen - Cantor Fitzgerald

Douglas Tsao - H.C. Wainwright

Operator

Good day, and thank you for standing by. Welcome to the Roivant Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

And I would now like to hand the conference over to your speaker today, Ms. Stephanie Lee. Please go ahead.

Stephanie Lee

Good morning, and thanks for joining today's call to review Roivant's financial results for the second quarter ended September 30th, 2023, along with the business update. I'm Stephanie Lee with Roivant. Presenting today, we have Matt Gline, CEO of Roivant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com.

We'll also be providing the current slide numbers as we present to help you follow along. I'd like to remind you that we'll be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties.

And with that, I'll turn it over to Matt.

Matt Gline

Thank you, Stephanie, and good morning, everybody. Thank you for joining us on this call this morning. It has been a highly eventful quarter, but comparatively an uneventful call given that most of the major updates, including the Immunovant data from September and the sale of Telavant to Roche have already been discussed, but I'm looking forward to giving everyone our normal business update and taking the questions-and-answers.

The plan here is, I'll talk a little bit about where we are as a business. I'm going to remind everybody of the parameters of the sale of Telavant, we are going to give a brief overview of the data that Immunovant presented back in September, a little bit about the VTAMA launch, a brief reminder of the upcoming brepocitinib data, and then we'll wrap up with financials and Q&A.